While mutational analysis for EGFR, ALK, and ROS1 are standard for unresectable NSCLC [10,11], NGS analysis has not become routine and is not reimbursed by the National Health Insurance Program in Taiwan. Here, EGFR is linked to non-small cell lung carcinoma.